clinical trial · NCT05607108
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Squamous Cell Lung CancerZEN003694
brief summary
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
started
Nov 1, 2022
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Sep 23, 2026
official title
Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol